<DOC>
	<DOCNO>NCT00962936</DOCNO>
	<brief_summary>This study aim evaluate whether investigational monoclonal antibody , CT-011 , safe give help patient hepatitis C virus ( HCV ) . Monoclonal antibody type drug typically give infusion vein ( intravenously ) . Results trial help doctor obtain additional information regard safety efficacy CT-011 potential treatment HCV .</brief_summary>
	<brief_title>Safety Tolerability Study Monoclonal Antibody CT-011 Patients With Chronic Hepatitis C Genotype I Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patient 18 60 year age , gender . 2 . Biopsy proven infection Hepatitis C genotype 1 . 3 . Positive antiHCV . 4 . Chronically infect least 3 month diagnosis . 5 . ECOG performance status â‰¤ 1 . 6 . Previous therapy interferon +/ Ribavirin Peginterferon +/ Ribavirin ineligibility type therapy liver transplantation . 1 . Patients receive type anti viral treatment 3 month prior enrollment . 2 . Any history active malignancy . 3 . History major organ transplantation exist functional graft . 4 . Patients receive systemic concurrent therapy within last 4 week . 5 . Patients progress acute liver failure ( ALF ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>HCV Genotype I infection</keyword>
	<keyword>Liver disease</keyword>
</DOC>